Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta.

Estrogen receptor (ER) modulators produce distinct tissue-specific biological effects, but within the confines of the established models of ER action it is difficult to understand why. Previous studies have suggested that there might be a relationship between ER structure and activity. Different ER modulators may induce conformational changes in the receptor that result in a specific biological activity. To investigate the possibility of modulator-specific conformational changes, we have applied affinity selection of peptides to identify binding surfaces that are exposed on the apo-ERs alpha and beta and on each receptor complexed with estradiol or 4-OH tamoxifen. These peptides are sensitive probes of receptor conformation. We show here that ER ligands, known to produce distinct biological effects, induce distinct conformational changes in the receptors, providing a strong correlation between ER conformation and biological activity. Furthermore, the ability of some of the peptides to discriminate between different ER alpha and ER beta ligand complexes suggests that the biological effects of ER agonists and antagonists acting through these receptors are likely to be different.

[1]  J. Pike,et al.  Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. , 1995, Molecular endocrinology.

[2]  B. Bhavnani,et al.  Pharmacokinetics of 17 beta-dihydroequilin sulfate and 17 beta-dihydroequilin in normal postmenopausal women. , 1994, The Journal of clinical endocrinology and metabolism.

[3]  J. Polman,et al.  ERβ: Identification and characterization of a novel human estrogen receptor , 1996 .

[4]  R B Mazess,et al.  Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.

[5]  T. Bourne,et al.  Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial , 1994, The Lancet.

[6]  B. Bhavnani.  Pharmacokinetics and Pharmacodynamics of Conjugated Equine Estrogens: Chemistry and Metabolism , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[7]  B. O’Malley,et al.  Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. , 1993, Molecular endocrinology.

[8]  A. Conney,et al.  Functional role of estrogen metabolism in target cells: review and perspectives. , 1998, Carcinogenesis.

[9]  Sulistiyani,et al.  Effect of 17α-Dihydroequilin Sulfate, a Conjugated Equine Estrogen, and Ethynylestradiol on Atherosclerosis in Cholesterol-Fed Rabbits , 1995 .

[10]  B. O’Malley,et al.  In situ distinction between steroid receptor binding and transactivation at a target gene , 1991, Molecular and cellular biology.

[11]  H W Cole,et al.  Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators. , 1998, Journal of medicinal chemistry.

[12]  D. Toft,et al.  Steroid receptors and their associated proteins. , 1993, Molecular Endocrinology.

[13]  D. Williams,et al.  Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. , 1994, The Journal of clinical investigation.

[14]  B. O’Malley,et al.  Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.

[15]  V. Jordan.  The strategic use of antiestrogens to control the development and growth of breast cancer. , 1992, Cancer.

[16]  V. Jordan,et al.  Basic guide to the mechanisms of antiestrogen action. , 1998, Pharmacological reviews.

[17]  J. Shine,et al.  Sequence and expression of human estrogen receptor complementary DNA. , 1986, Science.

[18]  M. Subbiah.  Mechanisms of Cardioprotection by Estrogens , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[19]  K.,et al.  Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Stallcup,et al.  Enhancement of Estrogen Receptor Transcriptional Activity by the Coactivator GRIP-1 Highlights the Role of Activation Function 2 in Determining Estrogen Receptor Pharmacology* , 1998, The Journal of Biological Chemistry.

[21]  C. D. Jones,et al.  Molecular determinants of tissue selectivity in estrogen receptor modulators. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Evans,et al.  Zinc fingers: Gilt by association , 1988, Cell.

[23]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[24]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[25]  B. O’Malley,et al.  Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. , 1997, Molecular endocrinology.

[26]  David M. Heery,et al.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors , 1997, Nature.

[27]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.